These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31603909)

  • 1. Stabilization of α-synuclein oligomers using formaldehyde.
    Ruesink H; Reimer L; Gregersen E; Moeller A; Betzer C; Jensen PH
    PLoS One; 2019; 14(10):e0216764. PubMed ID: 31603909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.
    Paleologou KE; Kragh CL; Mann DM; Salem SA; Al-Shami R; Allsop D; Hassan AH; Jensen PH; El-Agnaf OM
    Brain; 2009 Apr; 132(Pt 4):1093-101. PubMed ID: 19155272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA.
    Becker K; Wang X; Vander Stel K; Chu Y; Kordower J; Ma J
    Mol Neurobiol; 2018 Nov; 55(11):8728-8737. PubMed ID: 29589283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
    Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
    Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
    Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
    J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
    Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
    Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FKBP12-immunopositive inclusions in patients with α-synucleinopathies.
    Honjo Y; Ayaki T; Horibe T; Ito H; Takahashi R; Kawakami K
    Brain Res; 2018 Feb; 1680():39-45. PubMed ID: 29246765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
    Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
    J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.
    Peelaerts W; Bousset L; Van der Perren A; Moskalyuk A; Pulizzi R; Giugliano M; Van den Haute C; Melki R; Baekelandt V
    Nature; 2015 Jun; 522(7556):340-4. PubMed ID: 26061766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an α-synuclein fibril and oligomer specific tracer for diagnosis of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy.
    Sevenich M; Honold D; Willuweit A; Kutzsche J; Mohrlüder J; Willbold D
    Neurochem Int; 2022 Dec; 161():105422. PubMed ID: 36252819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy.
    Nimmo JT; Verma A; Dodart JC; Wang CY; Savistchenko J; Melki R; Carare RO; Nicoll JAR
    Alzheimers Res Ther; 2020 Nov; 12(1):159. PubMed ID: 33256825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated α-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy.
    Donadio V; Incensi A; Rizzo G; Westermark GT; Devigili G; De Micco R; Tessitore A; Nyholm D; Parisini S; Nyman D; Tedeschi G; Eleopra R; Ingelsson M; Liguori R
    Brain; 2023 Mar; 146(3):1065-1074. PubMed ID: 35552610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of DNA aptamers that recognize α-synuclein oligomers using a competitive screening method.
    Tsukakoshi K; Abe K; Sode K; Ikebukuro K
    Anal Chem; 2012 Jul; 84(13):5542-7. PubMed ID: 22697251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin α-synuclein deposits differ in clinical variants of synucleinopathy: an in vivo study.
    Donadio V; Incensi A; El-Agnaf O; Rizzo G; Vaikath N; Del Sorbo F; Scaglione C; Capellari S; Elia A; Stanzani Maserati M; Pantieri R; Liguori R
    Sci Rep; 2018 Sep; 8(1):14246. PubMed ID: 30250046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of Noradrenaline to Native and Intermediate States during the Fibrillation of α-Synuclein Leads to the Formation of Stable and Structured Cytotoxic Species.
    Singh P; Bhat R
    ACS Chem Neurosci; 2019 Jun; 10(6):2741-2755. PubMed ID: 30917654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease and multiple system atrophy have distinct α-synuclein seed characteristics.
    Yamasaki TR; Holmes BB; Furman JL; Dhavale DD; Su BW; Song ES; Cairns NJ; Kotzbauer PT; Diamond MI
    J Biol Chem; 2019 Jan; 294(3):1045-1058. PubMed ID: 30478174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
    Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology.
    Longhena F; Faustini G; Spillantini MG; Bellucci A
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.